Miraculins Highlights New Peer-Reviewed Publications on SCOUT DS(R)

Miraculins Highlights New Peer-Reviewed Publications on SCOUT DS(R) 
Scientific Evidence Supporting Non-Invasive Diabetes Screening System
Continues to Build 
WINNIPEG, MANITOBA -- (Marketwired) -- 08/19/13 --  
Editors note: There is one photo associated with this press release. 
Miraculins Inc. (TSX VENTURE:MOM), ("Miraculins" or the "Company") a
medical diagnostic company focused on acquiring, developing and
commercializing diagnostic and risk assessment technologies for unmet
clinical needs, is pleased to announce five new SCOUT DS(R)
publications in peer-reviewed journals since April 2013. These
studies include research demonstrating the superiority of the SCOUT
DS(R) system when compared to random capillary glucose in an at-risk
population, published in Diabetes Research and Clinical Practice in
April 2013.  
"The recent publication of a number of SCOUT DS(R) studies in
well-respected, peer-reviewed journals, highlights the increasing
scientific evidence in support of this product, the world's first
non-invasive diabetes screening system," said Christopher J. Moreau,
President and Chief Executive Officer of Miraculins Inc. "The SCOUT
DS(R) is designed to provide a highly sensitive and convenient method
for screening of pre-diabetes and type 2 diabetes based on the
presence of diabetes-related biomarkers found in skin and we are
pleased to see the supporting scientific evidence continue to build." 
Recent SCOUT DS(R) publications are as follows: 
1. Tentolouis N. et al. Screening for HbA1c-defined prediabetes and
diabetes in an at-risk Greek population: Performance comparison of
random capillary glucose, the ADA diabetes risk test and skin
fluorescence spectroscopy. Diabetes Research and Clinical Practice
2013: 100(1): 39-45.  
2. Cleary PA. et al. Clinical and Technical Factors Associated with
Skin Intrinsic Fluorescence in Subjects with Type 1 Diabetes from the
DCCT/EDIC Study. Diabetes Technology and Therapeutics 2013:15(6):
3. Orchard TJ. et al. The Association of Skin-Intrinsic Fluorescence
With Type 1 Diabetes Complications in the DCCT/EDIC Study. (Published
online ahead of print June 28, 2013 Diabetes Care. Doi:
4. Olson BP. et al. Noninvasive Skin Fluorescence Spectroscopy Is
Comparable to Hemoglobin A1c an
d Fasting Plasma Glucose for Detection
of Abnormal Glucose Tolerance. Journal of Diabetes Science and
Technology 2013: 7(4): 990-1000.  
5. Shah S. et al. Advanced glycation endproducts in children with
diabetes. (Published online ahead of print August 5, 2013) Journal of
Pediatrics. Doi: 10.1016/jpeds.2013.06.044.  
In addition to these current publications, the clinical and
scientific evidence underlying the SCOUT DS(R) has been developed in
a number of clinical studies, across more than 30 clinical sites and
over 3,000 patients.  
Key clinical evidence for SCOUT DS(R) includes: 
1. ENGINE trial, a prospective, multi-centre study which was
conducted in 2010 on more than 500 patients at 12 clinical sites in
the United States. The purpose of the ENGINE trial was a real-world
comparison of SCOUT DS(R)  to fasting plasma glucose (FPG) and HbA1c
(glycated haemoglobin) for diabetes screening, and using a 2-hour
oral glucose tolerance test (OGTT) as the reference standard. FPG and
HbA1c are common laboratory based diabetes tests. The study concluded
that SCOUT DS(R) detection of abnormal glucose tolerance was
equivalent to FPG and HbA1c at false positive rates that are
appropriate for screening, and furthermore the sensitivity of SCOUT
DS(R) was higher than that of FPG and HbA1c at their common diabetes
screening thresholds.  
2. POSSE trial, a 2012 comparison of SCOUT DS(R) against random
capillary glucose (RCG) in a workplace screening model of more than
650 individuals in a four day period. The trial was conducted in
collaboration with Blue Cross/Blue Shield of Louisiana using HbA1c as
the reference standard. The study concluded that SCOUT DS(R) was more
accurate than RCG in this setting.  
3. NSEEDS trial, a 2010/2011, multi-centre comparison of SCOUT DS(R)
against FPG and Hba1c with 2-hour OGTT as the reference standard. In
addition to demonstrating equivalence or superiority to existing
methods, the study demonstrated reproducibility of the SCOUT DS(R)
and showed that the coefficient of variation (CV) of the SCOUT DS(R)
was equivalent to FPG.  
4. GREECE trial, a 2011/2012, comparison of SCOUT DS(R) against
random capillary glucose (RCG) and the American Diabetes Association
diabetes risk test (ADADRT) with a 2-hour OGTT as the reference
standard. The study demonstrated that the SCOUT DS(R) was superior to
RCG and ADADRT for detection of diabetes and pre-diabetes.  
5.  TCOYD trial, a 2010/2011, assessment of SCOUT DS(R) as an
accurate tool for identifying individuals with previously diagnosed
type 2 diabetes. The study demonstrated the SCOUT DS(R) ability to
correctly identify 93.7% of previously identified diabetic
About the SCOUT DS(R) 
The SCOUT DS(R) system is the first non-invasive diabetes screening
system designed to provide a highly sensitive and convenient method
for screening for pre-diabetes and type 2 diabetes based on the
presence of diabetes-related biomarkers found in skin. Unlike current
screening methods, a SCOUT DS(R) test requires no blood draw, no
fasting, and no waiting for a lab result. The product has been used
and validated in thousands of patients around the world. The SCOUT
DS(R) has received clearance from Health Canada for commercial
distribution, has been granted a CE Mark in the European Union, and
is also cleared for sale in Mexico. For more information visit
About Miraculins Inc. 
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive technologies for unmet
clinical needs. A significant number of promising diagnostic
opportunities remain un-commercialized because of the sizable gap
between the discovery stage, when research institutions are typically
involved, and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology
that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. The Company's
preeclampsia program is partnered with Alere Inc., one of the world's
largest diagnostic companies. For more information visit
Caution Regarding Forward-Looking Information 
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, including, without limitation,
our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements.  
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are appl
ied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things: Miraculins' early stage of development,
lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development,
rapid technological change, uncertainties related to forecasts,
competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters
and risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to anticipate
and manage the risks associated with the foregoing. Additional
information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found
in the body of this news release. Miraculins cautions that the
foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking
statements to make decisions with respect to Miraculins investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.  
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statement.  
PreVu(R) and SCOUT DS(R) are registered trademarks of Miraculins Inc.
All Rights Reserved. 2013. 
To view the image associated with this press release, please visit
the following link:
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. 
Image Available:
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-453-1596 (FAX)
Press spacebar to pause and continue. Press esc to stop.